Condition deep-dive · 6 min read

Premenstrual Syndrome (PMS) — the supplement evidence

Updated 2026-05-13 · Reviewed by SupplementScore editors · No sponsorships

PMS is a constellation of physical, emotional, and behavioural symptoms occurring in the luteal phase (typically 1–2 weeks before menses) and resolving within a few days of period onset. Up to 80% of menstruating people experience some symptoms; about 20–30% have clinically significant PMS; 3–8% meet criteria for the more severe PMDD (premenstrual dysphoric disorder). This page covers the lighter-to-moderate end. For severe affective symptoms warranting SSRI consideration, see the PMDD page. The strongest supplement evidence is for calcium (with vitamin D), chasteberry (Vitex agnus-castus), B6, and to a lesser degree magnesium and saffron.

The supplement stack with trial evidence

Tier 1 evidence · The strongest single-supplement signal

Calcium (with vitamin D adequacy)

1,000–1,200 mg elemental calcium daily, split into 2 doses with meals; vitamin D 1,000–2,000 IU/day for adequacy

The Thys-Jacobs 1998 RCT (n=466) established 1,200 mg/day calcium reduces PMS symptoms by ~48% over three cycles vs ~30% on placebo — a meaningful effect size. Subsequent trials and a meta-analysis confirm the direction. Vitamin D adequacy may matter independently. This is the highest-leverage single supplement intervention in PMS.

Tier 1 evidence · Particularly strong for breast tenderness and mood symptoms

Chasteberry (Vitex agnus-castus, standardised extract)

20–40 mg/day standardised extract (e.g., Ze 440, BNO 1095); allow 3 cycles for full effect

Multiple RCTs and meta-analyses support chasteberry for PMS, particularly breast tenderness (mastalgia), bloating, and irritability. The Schellenberg 2001 BMJ RCT established the standardised extract at 20 mg/day reduces total PMS score by ~50%. Mechanism is thought to involve dopaminergic effect on prolactin. Effects build over 3 cycles.

Tier 2 evidence · Mood and physical symptoms

Vitamin B6 (P5P or pyridoxine)

50–100 mg/day pyridoxine or 25–50 mg P5P; cap at 100 mg/day to avoid neuropathy risk

The Wyatt 1999 BMJ meta-analysis pooled 9 trials (n=940) and showed B6 at up to 100 mg/day reduced PMS symptoms more than placebo (OR 2.32 for overall improvement). Higher doses don't add benefit and risk reversible peripheral neuropathy at chronic intake >200 mg/day. Cap at 100 mg.

Tier 2 evidence · Mood, water retention, headache

Magnesium (citrate or glycinate)

200–360 mg elemental Mg/day, particularly in the luteal phase; with meals

Several small RCTs show magnesium reduces PMS-related mood symptoms, fluid retention, and menstrual headaches. The Walker 1998 trial used 200 mg/day Mg from cycle day 15 to next menses. Stacks well with B6 — combined evidence is consistent.

Tier 2 evidence · Mood-dominant PMS

Saffron extract (Crocus sativus)

28–30 mg/day standardised extract; allow 2–3 cycles

The Agha-Hosseini 2008 BJOG RCT (n=50) showed saffron 30 mg/day reduced PMS symptom score and depression score over two cycles. Reasonable for mood-dominant PMS.

What to skip

Evening primrose oil (EPO) for general PMS — better-quality meta-analyses show no benefit for general PMS; possible small effect for cyclical mastalgia only. Often over-marketed as "the PMS supplement."
Black cohosh "for PMS" — has menopause evidence; PMS evidence is weak, and hepatic safety signals make it a poor first-line PMS choice.
Wild yam / "natural progesterone" creams — no clinical PMS evidence; wild yam does not convert to progesterone in vivo.
"Hormone balancing" proprietary blends without standardised actives — pay for studied extracts at studied doses.
High-dose B6 (>200 mg/day chronic) — reversible peripheral neuropathy risk; cap at 100 mg/day.
Diuretic herbs (juniper, parsley seed) for cyclic bloating — electrolyte effects without meaningful symptom improvement.

The medical framework that helps when supplements don't

Symptom tracking (≥2 cycles) using DRSP or PRISM — confirms cyclic pattern, distinguishes PMS from underlying depression or anxiety.
SSRIs (fluoxetine, sertraline, escitalopram, paroxetine) — first-line for PMDD; effective even with luteal-phase-only dosing. Discuss with GP/OBGYN.
Combined oral contraceptives (particularly drospirenone-containing) — Yaz / Yasmin have FDA approval for PMDD; reasonable option for both contraception and PMS.
GnRH agonists (rare cases) — for severe PMDD unresponsive to SSRIs and OCP.
Aerobic exercise, sleep regularity, alcohol/caffeine reduction in luteal phase — lifestyle adjuncts with reasonable evidence.
CBT — for the cognitive component, reasonable adjunct.

Distinguishing PMS from underlying mood disorders. If symptoms persist into the follicular phase or never fully remit, this isn't PMS — it's a primary mood disorder with cyclic exacerbation. Two cycles of prospective daily tracking distinguish these. Persistent or severe symptoms — particularly thoughts of self-harm — warrant clinical evaluation.

Practical quick-start stack. Calcium 600 mg + vitamin D 1,000 IU twice daily with meals, daily through the cycle (not just luteal). Chasteberry standardised extract 20 mg every morning, daily, for 3 cycles minimum. B6 (P5P) 50 mg/day. Magnesium glycinate 200 mg at bedtime. Track symptoms prospectively for 3 cycles using DRSP or PRISM. If severe mood symptoms persist, see GP/OBGYN about SSRIs or PMDD-approved OCP.

What to track

Daily Record of Severity of Problems (DRSP) or PRISM Calendar for 2–3 cycles to confirm cyclic pattern. Note breast tenderness, bloating, irritability, low mood, sleep disturbance, appetite changes, physical pain. Track when symptoms start (luteal phase day) and resolve (follicular phase day) to confirm timing. Re-evaluate at 3 cycles on stack — partial responders may benefit from medication adjuncts.